The Future Of Biomedical Funding Depends On You

Americans today live longer and are healthier in general than any other time in history. Much of this success is due to the government's willingness to strongly support biomedical research. Unfortunately, this support is constantly under attack despite rapid advances in molecular technology that potentially could offer medical treatments or cures. Traditionally, biomedical scientists and physicians have not been effective as political activists. As a group we have been more involved in runnin

Written byRaymond Dubois
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Americans today live longer and are healthier in general than any other time in history. Much of this success is due to the government's willingness to strongly support biomedical research. Unfortunately, this support is constantly under attack despite rapid advances in molecular technology that potentially could offer medical treatments or cures.

Traditionally, biomedical scientists and physicians have not been effective as political activists. As a group we have been more involved in running our laboratories, minding our own business, and assuming that the rest of the world would appreciate our lofty altruism enough to keep those research dollars rolling in.

If this quiet self-absorption worked in the past, it certainly does not today. Scientists and physician- investigators are under unprecedented pressure to scrounge for research dollars and justify their professional existence. Case in point: Only about 10 percent to 20 percent of submitted research applications are currently funded, meaning that ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies